<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Inhibition of <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor offers a novel approach to prevention of <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e> but has not yet been demonstrated to show efficacy on clinically relevant end points </plain></SENT>
<SENT sid="1" pm="."><plain>ARC1779 is an aptamer that inhibits the prothrombotic function of <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor by binding to the A1 domain of <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor and thereby blocking its interaction with <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Phase 1 studies suggest it inhibits platelet aggregation with less increase in <z:mp ids='MP_0001914'>bleeding</z:mp> than conventional antiplatelet agents </plain></SENT>
<SENT sid="3" pm="."><plain>The effect of ARC 1779 on <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral emboli</z:e> immediately after carotid endarterectomy was investigated in a randomized clinical trial </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Patients undergoing carotid endarterectomy were randomized double-blind to ARC1779 or placebo administered intravenously </plain></SENT>
<SENT sid="5" pm="."><plain>Transcranial Doppler recording, to detect cerebral embolic signals, was performed in the first 3 hours postoperatively </plain></SENT>
<SENT sid="6" pm="."><plain>The primary end point was time to first embolic signals </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Thirty-six patients were recruited, 18 in each arm </plain></SENT>
<SENT sid="8" pm="."><plain>The Kaplan-Meier median time to first embolic signals was 83.6 minutes for ARC1779 compared with 5.5 minutes for placebo </plain></SENT>
<SENT sid="9" pm="."><plain>Using Cox proportional hazards embolic signals occurred statistically significantly later on ARC1779 (P=0.007) </plain></SENT>
<SENT sid="10" pm="."><plain>Reduced embolic signals counts were correlated with inhibition of <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor activity (P=0.03) </plain></SENT>
<SENT sid="11" pm="."><plain>Increased perioperative <z:mp ids='MP_0001914'>bleeding</z:mp> and <z:hpo ids='HP_0001903'>anemia</z:hpo> were seen with ARC1779 </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor inhibition reduces <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> in humans </plain></SENT>
<SENT sid="13" pm="."><plain>It may play a role in treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>The extent to which <z:mp ids='MP_0001914'>bleeding</z:mp> complications occur in nonoperated patients needs to be assessed in further studies </plain></SENT>
<SENT sid="15" pm="."><plain>Clinical Trial Registration- URL: http://clinicaltrials.gov </plain></SENT>
<SENT sid="16" pm="."><plain>Unique identifier: NCT00742612 </plain></SENT>
</text></document>